| Code: MTA14399 | Publication Date: Oct 2026 |
The following is a data-backed list of the leading Urea Cycle Disorders companies, compiled through 6Wresearch's proprietary research and validated by in-house industry analysts. Abbott Laboratories, Takeda Pharmaceutical Company currently lead the competitive landscape, alongside several other established players shaping the Global Urea Cycle Disorders Market.
For detailed forecasts, data tables, and competitive benchmarking,
Explore the full Global Urea Cycle Disorders Market.
| Company Name | Abbott Laboratories |
|---|---|
| Established Year | 1888 |
| Headquarters | Abbott Park, Illinois, United States |
| Official Website | Click Here |
Abbott Laboratories is a global healthcare giant manufacturing specialized medical nutrition products, therapeutic formulas, and metabolic diets designed for infants and children diagnosed with inborn errors of metabolism such as PKU and MSUD.
| Company Name | Takeda Pharmaceutical Company Limited |
|---|---|
| Established Year | 1781 |
| Headquarters | Tokyo, Japan |
| Official Website | Click Here |
Takeda Pharmaceutical Company is a biopharmaceutical pioneer specializing in rare disease therapies, delivering enzyme replacement treatments and innovative biologics for lysosomal storage disorders and hereditary metabolic conditions.
| Company Name | Spyre Therapeutics, Inc. |
|---|---|
| Established Year | 2013 |
| Headquarters | Waltham, Massachusetts, United States |
| Official Website | Click Here |
Spyre Therapeutics is a biotechnology enterprise focused on developing novel biological therapies and engineered human enzymes to address rare metabolic diseases and inflammatory conditions.
| Company Name | B. Braun Melsungen AG |
|---|---|
| Established Year | 1839 |
| Headquarters | Melsungen, Germany |
| Official Website | Click Here |
B. Braun Melsungen AG is an international healthcare manufacturer offering specialized clinical nutrition systems, amino acid solutions, and parenteral infusion products essential for managing patients with severe metabolic imbalances.
| Company Name | Orpharma Pty Ltd. |
|---|---|
| Established Year | 2011 |
| Headquarters | Melbourne, Victoria, Australia |
| Official Website | Click Here |
Orpharma Pty Ltd. is a specialized pharmaceutical company focused on the acquisition, development, and commercialization of orphan drugs and medical nutrition products for patients suffering from rare genetic and metabolic disorders.
| Company Name | Pfizer Inc. |
|---|---|
| Established Year | 1849 |
| Headquarters | New York City, New York, United States |
| Official Website | Click Here |
Pfizer Inc. is a leading biopharmaceutical corporation with a dedicated rare disease division, developing targeted gene therapies, small molecule therapeutics, and endocrinology solutions for rare metabolic and genetic conditions.
| Company Name | Arcturus Therapeutics Holdings Inc. |
|---|---|
| Established Year | 2013 |
| Headquarters | San Diego, California, United States |
| Official Website | Click Here |
Arcturus Therapeutics is a messenger RNA (mRNA) medicine company developing targeted therapeutics and vaccines, utilizing proprietary LUNAR lipid-mediated delivery systems to treat rare metabolic disorders like OTC deficiency.
| Company Name | Cambrooke Therapeutics |
|---|---|
| Established Year | 2000 |
| Headquarters | Ayer, Massachusetts, United States |
| Official Website | Click Here |
Cambrooke Therapeutics is a medical nutrition developer producing specialized low-protein foods, amino acid formulas, and dietary management solutions for individuals living with PKU, tyrosinemia, and other metabolic diseases.
| Company Name | Acer Therapeutics Inc. (Part of Zevra Therapeutics) |
|---|---|
| Established Year | 2013 |
| Headquarters | Newton, Massachusetts, United States |
| Official Website | Click Here |
Acer Therapeutics (acquired by Zevra Therapeutics) is a pharmaceutical firm focused on developing and commercializing therapies for rare, life-threatening metabolic diseases, including urea cycle disorders (UCDs).
| Company Name | Horizon Therapeutics plc (A Subsidiary of Amgen) |
|---|---|
| Established Year | 2008 |
| Headquarters | Dublin, Ireland |
| Official Website | Click Here |
Horizon Therapeutics is a biopharmaceutical leader specializing in rare, autoimmune, and severe inflammatory diseases, offering targeted enzyme therapies to manage chronic refractory gout and rare metabolic conditions.
ISO 9001:2015 CERTIFIED
Quality Management System for market research & advisory services
Cert. No. 3050261008135Q